Hedge Funds Are Betting On Vanda Pharmaceuticals Inc. (VNDA)

Now, key money managers were leading the bulls’ herd. OrbiMed Advisors, managed by Samuel Isaly, assembled the most valuable call position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). OrbiMed Advisors had $12.5 million invested in the company at the end of the quarter. Steve Cohen’s Point72 Asset Management also initiated a $9 million position during the quarter. The following funds were also among the new VNDA investors: Ken Greenberg and David Kim’s Ghost Tree Capital, Glenn Russell Dubin’s Highbridge Capital Management, and Ken Griffin’s Citadel Investment Group.

Let’s check out hedge fund activity in other stocks – not necessarily in the same industry as Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) but similarly valued. We will take a look at Live Oak Bancshares Inc (NASDAQ:LOB), Barnes & Noble Education Inc (NYSE:BNED), Albany Molecular Research, Inc. (NASDAQ:AMRI), and Greenhill & Co., Inc. (NYSE:GHL). All of these stocks’ market caps match VNDA’s market cap.

As you can see these stocks had an average of 11.75 hedge funds with bullish positions and the average amount invested in these stocks was $75 million. That figure was $321 million in VNDA’s case. Greenhill & Co., Inc. (NYSE:GHL) is the most popular stock in this table. On the other hand Live Oak Bancshares Inc (NASDAQ:LOB) is the least popular one with only 4 bullish hedge fund positions. Compared to these stocks Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers and growing fonder of it still, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None